These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21972208)

  • 1. Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.
    Valent P
    Haematologica; 2011 Oct; 96(10):1395-7. PubMed ID: 21972208
    [No Abstract]   [Full Text] [Related]  

  • 2. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.
    Breccia M; Latagliata R; Stagno F; Luciano L; Gozzini A; Castagnetti F; Fava C; Cavazzini F; Annunziata M; Russo Rossi A; Pregno P; Abruzzese E; Vigneri P; Rege-Cambrin G; Sica S; Pane F; Santini V; Specchia G; Rosti G; Alimena G
    Haematologica; 2011 Oct; 96(10):1457-61. PubMed ID: 21685471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).
    Visani G; Breccia M; Montefusco E; Morra E; Santini V; Isidori A
    Haematologica; 2011 Apr; 96(4):e23-4; author reply e25. PubMed ID: 21454871
    [No Abstract]   [Full Text] [Related]  

  • 4. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib in chronic myelogenous leukemia.
    Chu SC; Tang JL; Li CC
    N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment-free remission after stopping second-line dasatinib.
    Ross DM
    Lancet Haematol; 2015 Dec; 2(12):e506-7. PubMed ID: 26686401
    [No Abstract]   [Full Text] [Related]  

  • 7. Favorable conception and pregnancy involving a male patient affected by chronic myeloid leukemia while taking dasatinib.
    Gentile M; Guido M; Lucia E; Vigna E; Mazzone C; Recchia AG; Morabito F
    Leuk Lymphoma; 2014 Mar; 55(3):709-10. PubMed ID: 23741978
    [No Abstract]   [Full Text] [Related]  

  • 8. Dasatinib-induced response in a rare case of chronic lymphocytic leukaemia associated with chronic myeloid leukaemia.
    Tecchio C; Nichele I; Todeschini G; Pizzolo G; Ambrosetti A
    Br J Haematol; 2009 Jul; 146(2):222-3. PubMed ID: 19466973
    [No Abstract]   [Full Text] [Related]  

  • 9. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
    Jabbour E; Cortes J; Kantarjian H
    Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?
    Paydas S
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):242-7. PubMed ID: 24210599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American Society of Hematology annual meeting.
    Fricker J
    Lancet Oncol; 2008 Jan; 9(1):13. PubMed ID: 18183660
    [No Abstract]   [Full Text] [Related]  

  • 12. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
    Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of the new patient with CML in chronic phase.
    Marin D
    Curr Hematol Malig Rep; 2013 Mar; 8(1):37-42. PubMed ID: 23381448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Bcr-Abl-positive leukemias with dasatinib.
    Hochhaus A
    Expert Rev Anticancer Ther; 2007 Nov; 7(11):1529-36. PubMed ID: 18020922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematology: dasatinib regimens for patients with chronic myeloid leukemia.
    Guilhot F; Roy L
    Nat Rev Clin Oncol; 2009 Dec; 6(12):680-2. PubMed ID: 19942922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.
    Ustun C; Randall N; Podgaetz E; Amin K; Dincer HE
    Thorax; 2015 Jul; 70(7):701-4. PubMed ID: 25935168
    [No Abstract]   [Full Text] [Related]  

  • 17. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Leuk Lymphoma; 2007 Apr; 48(4):802-4. PubMed ID: 17454640
    [No Abstract]   [Full Text] [Related]  

  • 18. New drugs: paliperidone, dasatinib, and decitabine.
    Hussar DA
    J Am Pharm Assoc (2003); 2007; 47(2):298-302. PubMed ID: 17510013
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.
    Kim D; Goh HG; Kim SH; Cho BS; Kim DW
    Int J Hematol; 2011 Oct; 94(4):361-371. PubMed ID: 21901399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment.
    Chang H; Hung YS; Chou WC
    Int J Infect Dis; 2014 Aug; 25():165-7. PubMed ID: 24932855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.